Dupilumab Treatment in Pediatric Patients Aged 6–11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review

References

• Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417–428.e2. doi:10.1016/j.anai.2020.12.020
   PubMed Web of Science ®Google Scholar
• Paller AS, Guttman-Yassky E, Schuttelaar ML, et al. Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: interim results from the PEDISTAD real-world registry. J Am Acad Dermatol. 2022;87(5):1104–1108. doi:10.1016/j.jaad.2022.01.018
   PubMed Web of Science ®Google Scholar
• Barbarot S, Silverberg JI, Gadkari A, et al. The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study. J Pediatr. 2022;246:220–226.e5. doi:10.1016/j.jpeds.2022.04.027
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Weidinger S, et al. Children with atopic dermatitis (AD) have a high burden of atopic comorbidities: results from a large worldwide survey. J Allergy Clin Immunol. 2021;147(2):AB31. doi:10.1016/j.jaci.2020.12.149
   Web of Science ®Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. doi:10.1016/j.jaad.2014.03.030
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi:10.1111/jdv.18345
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904–1926. doi:10.1111/jdv.18429
   PubMed Web of Science ®Google Scholar
• Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: international Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768–775. doi:10.1111/bjd.15928
   PubMed Web of Science ®Google Scholar
• Senner S, Seegräber M, Frey S, Kendziora B, Eicher L, Wollenberg A. Dupilumab for the treatment of adolescents with atopic dermatitis. Expert Rev Clin Immunol. 2020;16(7):641–650. doi:10.1080/1744666X.2020.1801420
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623–633. doi:10.1016/j.jaad.2017.06.042
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Dupilumab, Highlights of Prescribing Information; 2022. Available from: https://www.regeneron.com/downloads/dupixent_fpi.pdf. Accessed June 9, 2023.
   Google Scholar
• European Medicines Agency. Dupilumab Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf. Accessed June 9, 2023.
   Google Scholar
• Beck LA, Cork MJ, Amagai M, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innov. 2022;2(5):100131. doi:10.1016/j.xjidi.2022.100131
   PubMedGoogle Scholar
• Bissonette R, Leung DYM, Bologna G, Levit NA, Rossi AB, Zhang A. Dupilumab treatment restores skin barrier function and improves clinical and patient reported outcomes in adults and adolescents with moderate to severe atopic dermatitis. J Am Acad Dermatol. 2022;87(Suppl 3):AB160. doi:10.1016/j.jaad.2022.06.670
   Web of Science ®Google Scholar
• Berdyshev E, Goleva E, Bissonnette R, et al. Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy. 2022;77(11):3388–3397. doi:10.1111/all.15432
   PubMed Web of Science ®Google Scholar
• Callewaert C, Nakatsuji T, Knight R, et al. IL-4Rα blockade by dupilumab decreases Staphylococcus aureus colonization and increases microbial diversity in atopic dermatitis. J Invest Dermatol. 2020;140(1):191–202.e7. doi:10.1016/j.jid.2019.05.024
   PubMed Web of Science ®Google Scholar
• Lee S-J, Kim S-E, Shin K-O, Park K, Lee SE. Dupilumab therapy improves stratum corneum hydration and skin dysbiosis in patients with atopic dermatitis. Allergy Asthma Immunol Res. 2021;13(5):762–775. doi:10.4168/aair.2021.13.5.762
   PubMed Web of Science ®Google Scholar
• Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–1519. doi:10.1001/archderm.140.12.1513
   PubMedGoogle Scholar
• Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. J Am Acad Dermatol. 2016;75(4):681–687.e11. doi:10.1016/j.jaad.2016.05.028
   PubMed Web of Science ®Google Scholar
• Abuabara K, Ye M, Margolis DJ, et al. Patterns of atopic eczema disease activity from birth through midlife in 2 British birth cohorts. JAMA Dermatol. 2021;157(10):1191–1199. doi:10.1001/jamadermatol.2021.2489
   PubMed Web of Science ®Google Scholar
• Huang A, Cho C, Leung DYM, Brar K. Atopic dermatitis: early treatment in children. Curr Treat Options Allergy. 2017;4(3):355–369. doi:10.1007/s40521-017-0140-6
   PubMedGoogle Scholar
• Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013;24(5):476–486. doi:10.1111/pai.12095
   PubMed Web of Science ®Google Scholar
• Weidinger S, Simpson EL, Eckert L, et al. 15115 The patient-reported disease burden in pediatric patients with atopic dermatitis: a cross-sectional study in the United States, Canada, Europe, and Japan. J Am Acad Dermatol. 2020;83(Suppl 6):AB29. doi:10.1016/j.jaad.2020.06.203
   Web of Science ®Google Scholar
• Drucker AM, Wang AR, Li W-Q, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the national eczema association. J Invest Dermatol. 2017;137(1):26–30. doi:10.1016/j.jid.2016.07.012
   PubMed Web of Science ®Google Scholar
• Kruse LL, Cices A, Fishbein AB, Paller AS. Neurocognitive function in moderate-severe pediatric atopic dermatitis: a case-control study. Pediatr Dermatol. 2019;36(1):110–114. doi:10.1111/pde.13710
   PubMed Web of Science ®Google Scholar
• Wan J, Mitra N, Hooper SR, Hoffstad OJ, Margolis DJ. Association of atopic dermatitis severity with learning disability in children. JAMA Dermatol. 2021;157(6):1–7. doi:10.1001/jamadermatol.2021.0008
   PubMed Web of Science ®Google Scholar
• Hou A, Silverberg JI. Predictors and age-dependent pattern of psychologic problems in childhood atopic dermatitis. Pediatr Dermatol. 2021;38(3):606–612. doi:10.1111/pde.14588
   PubMed Web of Science ®Google Scholar
• Keller W, Vogel M, Prenzel F, et al. Atopic diseases in children and adolescents are associated with behavioural difficulties. BMC Pediatr. 2021;21(1):197. doi:10.1186/s12887-021-02663-7
   PubMed Web of Science ®Google Scholar
• Vittrup I, Andersen YMF, Droitcourt C, et al. Association between hospital-diagnosed atopic dermatitis and psychiatric disorders and medication use in childhood. Br J Dermatol. 2021;185(1):91–100. doi:10.1111/bjd.19817
   PubMed Web of Science ®Google Scholar
• Paller AS, Guttman-Yassky E, Irvine AD, et al. Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology. BMJ Open. 2020;10(3):e033507. doi:10.1136/bmjopen-2019-033507
   PubMed Web of Science ®Google Scholar
• Capozza K, Gadd H, Kelley K, Russell S, Shi V, Schwartz A. Insights from caregivers on the impact of pediatric atopic dermatitis on families: ‘I’m tired, overwhelmed, and feel like I’m failing as a mother’. Dermatitis. 2020;31(3):223–227. doi:10.1097/DER.0000000000000582
   PubMed Web of Science ®Google Scholar
• Mitchell AE. Bidirectional relationships between psychological health and dermatological conditions in children. Psychol Res Behav Manag. 2018;11:289–298. doi:10.2147/PRBM.S117583
   PubMed Web of Science ®Google Scholar
• de Bruin-Weller M, Schuttelaar M, Lynde CW, et al. Family impact of moderate-to-severe atopic dermatitis in children aged <12 years: results from 732 patients in the PEDIatric STudy in Atopic Dermatitis (PEDISTAD) observational study. J Am Acad Dermatol. 2022;87(Suppl 3):AB168. doi:10.1016/j.jaad.2022.06.703
   Web of Science ®Google Scholar
• Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283–289. doi:10.1016/j.det.2017.02.002
   PubMed Web of Science ®Google Scholar
• Cork MJ, Danby SG, Ogg GS. Atopic dermatitis epidemiology and unmet need in the United Kingdom. J Dermatolog Treat. 2020;31(8):801–809. doi:10.1080/09546634.2019.1655137
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491–498. doi:10.1016/j.jaad.2015.10.043
   PubMed Web of Science ®Google Scholar
• Shrestha S, Miao R, Wang L, Chao J, Yuce H, Wei W. Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the commercial, Medicare, and Medi-Cal databases. Adv Ther. 2017;34(8):1989–2006. doi:10.1007/s12325-017-0582-z
   PubMed Web of Science ®Google Scholar
• Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol. 2018;78(1):54–61.e1. doi:10.1016/j.jaad.2017.08.002
   PubMed Web of Science ®Google Scholar
• Lucae S, Schmidt-Grendelmeier P, Wütrich B, Kraft D, Valenta R, Linhart B. IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long-term systemic cyclosporine A treatment. Allergy. 2016;71(1):115–118. doi:10.1111/all.12711
   PubMed Web of Science ®Google Scholar
• Hijnen DJ, Knol E, Bruijnzeel-Koomen C, de Bruin-Weller M. Cyclosporin A treatment is associated with increased serum immunoglobulin E levels in a subgroup of atopic dermatitis patients. Dermatitis. 2007;18(3):163–165. doi:10.2310/6620.2007.06025
   PubMed Web of Science ®Google Scholar
• Vakharia PP, Silverberg JI. New and emerging therapies for paediatric atopic dermatitis. Lancet Child Adolesc Health. 2019;3(5):343–353. doi:10.1016/S2352-4642(19)30030-6
   PubMedGoogle Scholar
• Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol. 2003;148(1):128–133. doi:10.1046/j.1365-2133.2003.04934.x
   PubMed Web of Science ®Google Scholar
• Furue M, Terao H, Moroi Y, et al. Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis. J Dermatol. 2004;31(4):277–283. doi:10.1111/j.1346-8138.2004.tb00673.x
   PubMed Web of Science ®Google Scholar
• Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133(2):429–438. doi:10.1016/j.jaci.2013.07.049
   PubMed Web of Science ®Google Scholar
• Nguyen HL, Anderson KR, Tollefson MM. New and emerging therapies for pediatric atopic dermatitis. Paediatr Drugs. 2019;21(4):239–260. doi:10.1007/s40272-019-00342-w
   PubMed Web of Science ®Google Scholar
• Haddad E-B, Cyr SL, Arima K, McDonald RA, Levit NA, Nestle FO. Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis. Dermatol Ther. 2022;12(7):1501–1533. doi:10.1007/s13555-022-00737-7
   Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi:10.1056/NEJMoa1610020
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi:10.1016/S0140-6736(17)31191-1
   PubMed Web of Science ®Google Scholar
• de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–1101. doi:10.1111/bjd.16156
   PubMed Web of Science ®Google Scholar
• Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020;182(1):85–96. doi:10.1111/bjd.18476
   PubMed Web of Science ®Google Scholar
• Paller AS, Bansal A, Simpson EL, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020;21(1):119–131. doi:10.1007/s40257-019-00478-y
   PubMed Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56. doi:10.1001/jamadermatol
   PubMed Web of Science ®Google Scholar
• Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908–919. doi:10.1016/S0140-6736(22)01539-2
   PubMed Web of Science ®Google Scholar
• Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2021;184(5):857–870. doi:10.1111/bjd.19460
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293. doi:10.1016/j.jaad.2020.06.054
   PubMed Web of Science ®Google Scholar
• Paller AS, Wollenberg A, Siegfried E, et al. Laboratory safety of dupilumab in patients aged 6 to 11 years with severe atopic dermatitis: results from a phase III clinical trial. Paediatr Drugs. 2021;23(5):515–527. doi:10.1007/s40272-021-00459-x
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and ASTHMA. J Allergy Clin Immunol Pract. 2021;9(3):1133–1141. doi:10.1016/j.jaip.2020.09.063
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Beck LA, Sher L, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9(3):1212–1223.e6. doi:10.1016/j.jaip.2020.12.059
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Sher L, Paller A, et al. Dupilumab improves signs and symptoms of severe atopic dermatitis in children aged 6–11 years with and without comorbid asthma. J Allergy Clin Immunol. 2021;147(Suppl 2):AB32. doi:10.1016/j.jaci.2020.12.151
   Web of Science ®Google Scholar
• Beck LA, Wollenberg A, Paller A, et al. Dupilumab improves signs and symptoms of severe atopic dermatitis in children aged 6–11 years with and without comorbid allergic rhinitis. J Allergy Clin Immunol. 2021;147(Suppl 2):AB144. doi:10.1016/j.jaci.2020.12.523
   Web of Science ®Google Scholar